An unintended consequence of Sen. Richard Blumenthal’s advocacy for Medicare drug price reforms is that it underscores nothing has happened.
The U.S. Senate gave consumers – along with doctors, hospitals, and Connecticut’s health insurers — a win by approving bipartisan legislation that would require “direct-to-consumer” advertising to include the price of the medications, which are among the costliest on the market.
WASHINGTON — Like his predecessor, the new head of the Department of Health and Human Services, has sparked controversy and sharp criticism from Democrats, including Sens. Richard Blumenthal and Chris Murphy.
There’s a bully pulpit approach – think President-elect Donald J. Trump, who blasted pharmaceutical companies Wednesday – or the more industry-friendly concept of tying payments to whether the drugs deliver value, like fewer hospitalizations. There’s proposing legislation to increase transparency in drug pricing, or treating certain medications as critical goods that should be regulated like water and electricity.
The monthly October tracking poll from the Kaiser Family Foundation finds that issues relating to prescription drug prices and out-of-pocket spending far outrank proposals to address the shortcomings of the Affordable Care Act.
WASHINGTON — The nation’s health insurers are getting a boost from a new coalition that has taken up one of their key causes: halting big increases in drug prices and the cost of medicine. The goal: to press drug price increases and the high cost of many new medicines as an issue in the presidential campaign.